µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y433 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº Ç×»ýÁ¦ Antineoplastic antibiotics causing adverse effects in therapeutic use
Y434 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸é¿ª¾ïÁ¦Á¦ Immunosuppressive agents causing adverse effects in therapeutic use
Y435 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ê¼ºÈ­Á¦ ¹× ¾ËÄ®¸®È­Á¦ Acidifying and alkalizing agents causing adverse effects in therapeutic use
Y436 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È¿¼Ò·ù Enzymes, NEC causing adverse effects in therapeutic use
Y438 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ Other primarily systemic agents, NEC causing adverse effects in therapeutic use
Y438 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Á߱ݼӱæÇ×Á¦ Heavy-metal antagonists causing adverse effects in therapeutic use
Y439 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷Àû Àü½Å¾à¹° Primarily systemic agent, unspecified causing adverse effects in therapeutic use
Y44 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î Ç÷¾×¼ººÐ¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily affecting blood constituents causing adverse effects in therapeutic use
Y440 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â öÁ¦Á¦ ¹× ±âŸ Ç×ÀúÇ÷»ö¼Ò¼º ºóÇ÷Á¦Á¦ Iron preparations and other anti-hypochromic-anemia preparations causing adverse effects in therapeutic use
Y441 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î B12, ¿±»ê ¹× ±âŸ Ç×°Å´ëÀû¸ð±¸¼º ºóÇ÷ Á¦Á¦ Vitamin B12, folic acid and other anti-megaloblastic-anemia preparations causing adverse effects in therapeutic use
Y442 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°íÁ¦ Anticoagulants causing adverse effects in therapeutic use
Y443 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°í¼º ±æÇ×Á¦, ºñŸ¹Î K ¹× ±âŸ ÀÀ°íÁ¦ Anticoagulant antagonists, vitamin K and other coagulants causing adverse effects in therapeutic use
Y444 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Ç÷ÀüÁ¦[Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦] Antithrombotic drugs [platelet-aggregation inhibitors] causing adverse effects in therapeutic use
Y445 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç÷Àü¿ëÇØÁ¦ Thrombolitic drugs causing adverse effects in therapeutic use
Y446 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â õ¿¬ Ç÷¾× ¹× Ç÷¾× »ý»ê¹° Natural blood and blood products causing adverse effects in therapeutic use
Y447 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç÷Àå´ëÄ¡¹° Plasma substitutes causing adverse effects in therapeutic use
Y449 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Ç÷¾×¼ººÐ¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ Other and unspecified agent affecting blood constituents causing adverse effects in therapeutic use
Y45 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÁøÅëÁ¦, ÇØ¿­Á¦ ¹× Ç׿°ÁõÁ¦ Analgesics, antipyretics and anti-inflammatory drugs causing adverse effects in therapeutic use
Y450 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÆÆí ¹× °ü·Ã ÁøÅëÁ¦ Opioids and related analgesics causing adverse effects in therapeutic use
Y451 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ì¸®½Ç·¹ÀÌÆ® Salicylates causing adverse effects in therapeutic use
3871  3872  3873  3874  3875  [3876] 3877  3878  3879  3880